jRCT2080221473未知3 期
Open-label study to assess efficacy and safety of a single dose (i.v.) of NMA78 in patients with Dementia with Lewy Bodies (DLB) or Alzheimer's Disease (AD) and healthy volunteers (HV)
试验速览
- 阶段
- 3 期
- 入组人数
- 18
- 主要终点
- Safety
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Non-randomized, open-label
入排标准
- 年龄范围
- 35age old over 至 No limit(—)
- 性别
- All
入选标准
- •Healthy Japanese people.
- •Japanese patients clinically- diagnosed with DLB.
- •Japanese patients clinically- diagnosed with AD.
排除标准
- •People using following drugs: cocaine hydrochloride, mazindol, methylphenidate hydrochloride, sertraline hydrochloride.
- •Patients with hepatic, renal or hematopoietic dysfunction.
- •People with allergic reaction to alcohol or iodine.
- •Women who are pregnant, lactating or possibly pregnant.
结局指标
主要结局
Safety
subjective/objective symptoms, vital signs, electrocardiogram, clinical tests
Efficacy
diagnostic accuracy by reading committee
次要结局
未报告次要终点
研究者
相似试验
未知
3 期
Open-label study to assess efficacy and safety of a single dose (i.v.) of NMA78 in PS or ET patients and HVPS:Parkinson's Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy(PSP), ETJPRN-jRCT2080221472ihon Medi-Physics Co., Ltd.24
未知
3 期
Open-label study to assess efficacy and safety of a single dose (i.v.) of NMA78 in DLB or AD patients and HVDLB, ADJPRN-jRCT2080221473ihon Medi-Physics Co., Ltd.18
已完成
2 期
Open-label study to assess efficacy and safety of a single dose (i.v.) of NMK36 in subjects with high / low- grade glioma.jRCT2080222240Nihon Medi-Physics Co., Ltd.35
已完成
不适用
Treatment of severe chronic migraines with injections of stem cells obtained from patients' own fat tissueChronic migraine, refractory to treatmentNervous System DiseasesISRCTN72512465ew York Headache Center10
已完成
3 期
A study assessing safety and efficacy of MD-16 intraocular lens in patients with aphakic eye after cataract surgeryCataractJPRN-jRCT1080223821SANTEN PHARMACEUTICAL Co., LTD.59
